Search Results

Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced that it has completed its previously announced merger with Morphimmune.

Immunome and Morphimmune, a private biotechnology company focused on developing targeted oncology therapeutics, announced that they have entered into a definitive merger agreement.

MorphImmune, Inc. announced the appointment of Ronald Martell as the company’s President and CEO effective April 12, 2021.

-- The former President and CEO of Nuvelution Pharma also served as the CEO of three public biopharmaceutical companies, including Sevion and NeurogesX, and has overseen billions of dollars in industry transactions --

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027